Gyre Therapeutics, Inc. (GYRE) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin 8.5%, revenue growth 10.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $116.59M |
| Revenue (TTM) | $0.1B |
| Net Margin | 8.5% |
| Operating Margin (TTM) | -23.6% |
| Revenue Growth (YoY) | 10.2% |
| EPS Growth (YoY) | -57.1% |
| FCF Growth (YoY) | -97.0% |
| Price / Book | 5.39 |
| Price / Sales | 7.34 |
| FCF Yield | -0.3% |
| Altman Z-Score | 17.77 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
GYRE overview · GYRE earnings · GYRE KPIs · GYRE documents · GYRE ownership · GYRE peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.